LARIMAR THERAPEUTICS, INC. Debt Securities, Available-for-sale, Amortized Cost
LARIMAR THERAPEUTICS, INC. (LRMR) had Debt Securities, Available-for-sale, Amortized Cost of $63.59 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Credit Losses
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $63.59M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $22.47M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $51.39M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $85.23M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $63.59M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $22.47M 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $51.39M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $85.23M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $117.94M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $136.35M 10-Q · filed 2025-04-30 | |
| 2024-12-31 | $150.09M 10-K · filed 2026-03-19 | |
| 2024-09-30 | $168.28M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $193.90M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $128.91M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $59.96M 10-K · filed 2025-03-24 | |
| 2023-09-30 | $56.86M 10-Q · filed 2023-11-14 | |
| 2023-06-30 | $9.88M 10-Q · filed 2023-08-10 | |
| 2022-12-31 | $91.63M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $38.69M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $35.24M 10-Q · filed 2022-08-11 | |
| 2021-09-30 | $6.50M 10-Q · filed 2021-11-12 | |
| 2021-03-31 | $19.25M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $24.49M 10-K · filed 2022-03-25 | |
| 2020-09-30 | $1.00M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $1.01M 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $24.87M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $43.02M 10-Q · filed 2020-05-07 | |
| 2019-09-30 | $38.63M 10-Q · filed 2019-11-06 | |
| 2019-06-30 | $54.39M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $68.24M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $68.77M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $82.72M 10-Q · filed 2018-11-09 | |
| 2018-06-30 | $35.11M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $43.39M 10-Q · filed 2018-05-10 | |
| 2017-12-31 | $61.33M 10-K · filed 2019-03-14 | |
| 2017-09-30 | $74.02M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $74.31M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $88.37M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $96.92M 10-K · filed 2018-03-09 | |
| 2016-09-30 | $113.86M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $130.46M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $134.73M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $149.69M 10-K · filed 2017-03-10 | $149.69M 10-K · filed 2016-03-15 |
| 2015-09-30 | $165.22M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $136.61M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $127.31M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $57.39M 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |